Literature DB >> 27080173

Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I.

Paola Contini1, Simone Negrini1, Giorgia Bodini2, Cecilia Trucchi3, Gianluca Ubezio4, Paolo Strada4, Vincenzo Savarino2, Massimo Ghio1.   

Abstract

Granulocyte and monocyte apheresis has been used in different immune-mediated disorders, mainly inflammatory bowel diseases. The removal of activated leukocytes and several additional immunomodulatory mechanisms have been so far suggested to explain the anti-inflammatory effects of the treatment. Recent data indicate that, during centrifugation based apheresis, sHLA-I adsorbed to plastic circuits is able to induce TGFβ1 production in activated leukocytes. On these bases, the present study was aimed at analyzing if this model could be applied to a noncentrifugation based apheresis, such as granulocyte and monocyte apheresis. Ten patients with ulcerative colitis were enrolled. Every patient received 5 weekly apheresis treatments. Cellulose acetate beads removed from the column post-GMA were stained by fluorescent anticlass I mAb and examined by fluorescent microscope. Moreover, sFasL plasma concentration, TGFβ1 plasma levels, and the percentage of TGFβ1 positive neutrophils were evaluated before and immediately after each single apheresis. Immunofluorescent images revealed a homogeneous layer of a sHLA-I adsorbed to the surface of the beads recovered following the procedure. sFasL plasma concentration progressively increased both following the procedures and during inter-procedure periods. Consistently, also TGFβ1 plasma levels and the percentage of TGFβ1 positive neutrophils increased during the procedures with a meaningful relationship with sFasL plasma levels. Taken together, these findings suggest that the immunosuppressive effects attributed to granulocyte and monocyte apheresis might depend, at least in part, on the sensitivity of activated leucocytes to the bioactivity of sHLA-I molecules. J. Clin. Apheresis 32:49-55, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  TGFβ1; granulocytes and monocytes apheresis; inflammatory bowel diseases; sFasL; sHLA-I

Mesh:

Substances:

Year:  2016        PMID: 27080173     DOI: 10.1002/jca.21466

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  4 in total

Review 1.  TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.

Authors:  Sozaburo Ihara; Yoshihiro Hirata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2017-05-22       Impact factor: 7.527

Review 2.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

3.  Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis.

Authors:  Satoshi Tanida; Keiji Ozeki; Takuya Kanno; Takahito Katano; Naomi Sugimura; Hirotada Nishie; Hiroyasu Iwasaki; Mamoru Tanaka; Takaya Shimura; Eiji Kubota; Hiromi Kataoka
Journal:  J Clin Med Res       Date:  2021-11-20

4.  Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

Authors:  Guro Kristin Melve; Elisabeth Ersvaer; Geir Egil Eide; Einar K Kristoffersen; Øystein Bruserud
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.